Target intelligence / Profile preview

F-box protein 8 (FBXO8)

Target
FBXO8
Molecular classification
Enzyme (component of an E3 ubiquitin ligase complex), Ubiquitin-proteasome pathway protein, Guanine-nucleotide exchange factor (putative, based on domain structure)
01

Overview

FBXO8, or F-box protein 8, is a human protein encoded by the FBXO8 gene and is part of the F-box family, characterized by the F-box domain involved in protein ubiquitination[3]. FBXO8 serves as a substrate recognition subunit in the SCF (SKP1-Cullin-F-box) E3 ubiquitin ligase complex, regulating proteasomal degradation of key proteins[2][3]. It mediates noncanonical ubiquitination of the small GTPase Arf6, suppressing invasive activity in breast cancer cells and contributing to membrane remodeling and cell migration[1]. Loss or dysfunction of FBXO8 has been associated with increased cancer cell invasiveness, supporting its role as a tumor suppressor and potential target for cancer therapy[1][2][3]. The molecular actions and expression of FBXO8 are subject to modulation by epigenetic and post-translational mechanisms, making it a central player in cell signaling, protein turnover, and potentially tumor immune regulation[2][3].

Other names
FBX8FBXO8Fbx8 proteinSKP1-cullin-F-box protein 8
02

Mechanism of action

For theoretical drugs: inhibition or restoration of FBXO8 function would modulate Arf6 activity and substrate ubiquitination, affecting cell invasion and tumor suppressive mechanisms

03

Biological functions

Ubiquitination of substrate proteinsNoncanonical regulation of GTPase signaling (Arf6)Cell cycle controlSignal transduction, especially via SCF-mediated pathwaysRegulation of cell invasion and membrane remodeling
04

Disease associations

Cancer (breast, colon, lung: loss of FBXO8 expression implicated in increased invasiveness and malignancy)Tumorigenesis and immune escape (by modulating the stability of oncogenic and tumor suppressor proteins)Arthrogryposis, distal, type 10 (gene association)
05

Safety considerations

Potential risk for undesirable immunosuppression or altered tumor immune microenvironment if FBXO8 activity is targeted or modulatedSpecific safety concerns uncharacterized, as no approved drugs directly target FBXO8.
06

Interacting drugs

None specifically listed or clinically available targeting FBXO8 as of 2024; research is ongoing for targeting F-box family members for cancer and immunotherapy
07

Biomarkers

FBXO8 expression loss as a candidate biomarker for invasive breast cancer phenotype and possibly other cancers

Beyond the preview

Go deeper on F-box protein 8 (FBXO8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box protein 8 (FBXO8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call